Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Neurotrophin Stories

2013-01-09 08:27:04

SUNNYVALE, Calif., Jan. 9, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today presented positive preclinical efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data...

2012-11-27 08:27:42

SUNNYVALE, Calif., Nov. 27, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains. The striatum is located in the brain,...

2012-06-18 23:20:32

New approach reported in Restorative Neurology and Neuroscience Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects. Now, a group of scientists has successfully...

2012-06-06 02:24:40

SUNNYVALE, Calif., June 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing drug and diagnostic products for the treatment of Parkinson's disease and other nervous system disorders including Traumatic Brain Injury, today announced that it has been selected to participate in the National Investment Banking Association's 122nd Conference in New York City at Le Park Meridien Hotel June 7-8, 2012. Mr. Gerald Commissiong, Amarantus'...

2012-05-09 02:25:49

SUNNYVALE, Calif., May 9, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to participate in the Wall Street 1-2-1 Conference in Orlando, Florida at the Rosen Shingle Creek Resort May 8-11, 2012. Mr. Gerald Commissiong, Amarantus' President & CEO, will be a...

2012-05-01 02:31:31

SUNNYVALE, Calif., May 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to present in the Emerging Companies Showcase at the New York Biotechnology Association's 21st Annual Meeting on May 2nd, 2012 in New York City at the Marriott Marquis Hotel. Mr....

2012-04-26 02:25:08

SUNNYVALE, Calif. and MINNEAPOLIS, April 26, 2012 /PRNewswire/ -- Brewer Sports International (BSI), a globally diversified boutique services provider for professional athletes, sports agencies and various other organizations, and Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF, today announced the...

2012-04-23 11:21:23

With more than 1.7 million people sustaining a traumatic brain injury each year, the need to identify processes to limit inflammation and subsequent damage is critical. Approximately 275,000 people are hospitalized annually with traumatic brain injury, leaving 85,000 with long-term disabilities and taking the lives of more than 50,000. More than 5 million people live with disabilities caused by traumatic brain injuries, often the result of car accidents and falls. Direct and indirect costs...

2012-03-23 05:43:10

(Ivanhoe Newswire)-- A ravenous appetite may be what causes many overweight people to be obese. Researchers have found a mutation in a single gene is responsible for the inability of neurons to effectively send out appetite suppressing signals from the body to the correct area of the brain. A study suggests that there might be a way to stimulate expression of that gene to treat obesity caused by uncontrolled eating. Researchers found that a mutation in the brain-derived neurotrophic...

2012-03-19 04:53:45

The discovery offers clues about how to turn on brain sensitivity to leptin and insulin, hormones that turn off appetite Researchers at Georgetown University Medical Center have revealed how a mutation in a single gene is responsible for the inability of neurons to effectively pass along appetite suppressing signals from the body to the right place in the brain. What results is obesity caused by a voracious appetite. Their study, published March 18th on Nature Medicine's website,...